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ABSTRACT 
 
Background 
Increasing evidence suggests that inflammation may be linked to the pathogenesis of 
colorectal cancer. However, recently, two conflicting observational results were reported on 
the relationship between the inflammatory marker C-reactive protein (CRP) and the risk of 
colorectal cancer. Few epidemiologic studies have examined the association between 
inflammatory markers and the risk of colorectal cancer. 
 
Purpose 
We aimed to examine the association between WBC count and the risk of colon and rectal 
cancer in this prospective cohort study. 
 
Methods 
We prospectively examined the mortality and incidence risk for colon and rectal cancers 
among 424,419 Koreans (108,907 men and 315,512 women). The subjects were 40 to 95 years 
of age and from the Korean Cancer Prevention Study (KCPS) cohort. All subjects received 
medical examination from the National Health Insurance Corporation in 1993 and 1995. The 
maximum follow-up period was 10 years, from January 1, 1994 to December 31, 2003.  
 
Results 
An elevated WBC count was associated with a higher mortality risk of colon cancer 
(highest versus lowest quartile: men, 1.55, 95% CI 1.10-2.18, p for trend=0.0014; women, 
 v 
1.51, 95% CI 1.12-2.03, p for trend=0.0049). Similarly, an elevated WBC count was 
associated with a higher incidence risk of colon cancer (highest versus lowest quartile: men, 
1.38, 1.09-1.76, p for trend=0.0017; women, 1.46, 95% CI 1.20-1.78, p for trend=0.0003). A 
positive linear trend was also observed in non-smokers. There was no significant association 
between WBC count and the risk of rectal cancer. 
 
Conclusion 
Our findings demonstrate that an elevated WBC count is associated with an increase in both 
the mortality and incidence rates of colon cancer. These results support our hypothesis that 
inflammation increases the risk of colon cancer.  
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INTRODUCTION 
 
The incidence of colorectal cancer has been increasing gradually during the past several 
decades in Korea. In 1980, when the Central Cancer Registry began, colorectal cancers 
accounted for 5.8% of the total cancers (National Cancer Institute. 2003). In 1990 and 2002, 
this figure increased to 6.9% and 11.2%, respectively. With estimates of 11,000 new cases 
annually, colorectal cancer is the fourth most common cancer and the fourth leading cause of 
cancer-related mortality in Korea (Korea National Statistical Office. 2003). 
Considerable studies have examined factors that influence the development of colorectal 
cancer. Family histories of colorectal cancer (Durno, 2005), obesity (Moore, 2004), animal fat 
intake (Nagata, 2001), alcohol (Shimizu, 2003), cigarette smoking (Lüchtenborg, 2005), 
physical inactivity (Slattery, 2003), and insulin resistance (Jee, 2005) have been regarded as 
predisposing factors of colorectal cancer.  
Increasing evidence suggests that inflammation may be linked to the pathogenesis of 
colorectal cancer. Many studies have suggested a relationship between colorectal cancer and 
chronic inflammation. The risk of colorectal cancer increases in patients with long-standing 
inflammatory bowel diseases (Levin, 1992). In addition, several studies have consistently 
shown a risk reduction for the incidence of colorectal adenoma and cancer among regular and 
prolonged users of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) 
(Giovannucci, 1994; Giardiello, 1993). However, recently, two conflicting observational 
results were reported on the relationship between the inflammatory marker C-reactive protein 
(CRP) and the risk of colorectal cancer. A nested case-control study showed that individuals 
with C-reactive protein (CRP) concentrations in the highest quartile had a significantly higher 
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risk for the incidence of colon cancer compared with individuals in the lowest quartile 
(Erlinger, 2004). On the contrary, conflicting results were shown in another prospective study 
in which an elevated plasma CRP level was not a predictor of colorectal cancer, rather it was 
shown to be merely increased after the onset of colorectal cancer (Zhang, 2005). Few 
epidemiologic studies have examined the association between inflammatory markers and the 
risk of colorectal cancer. 
WBC count is also a marker of nonspecific inflammation. Hence, WBC was included and 
analyzed in this study to examine its relationship with the risk of colorectal cancer. We 
hypothesized that an elevated WBC count is associated with the risk of colorectal cancer. 
Further, we hypothesized that this association would be independent of smoking because 
WBC counts and CRP levels tend to be chronically elevated in smokers (Zalokar, 1981; Das, 
1985). To examine these hypotheses, we determined the risk of colon and rectal cancer 
associated with WBC count in this prospective cohort study. 
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METHODS 
 
Study Population 
 
The Korean Cancer Prevention Study (KCPS) is a prospective cohort study that was 
designed to assess risk factors for mortality, incidence, and hospital admission for cancer. The 
KCPS cohort was composed of government employees, teachers, and their dependents insured 
by the Korea Medical Insurance Corporation from 1992 through 1995. The subjects had at 
least one medical examination and completed a questionnaire during that period. In brief, the 
KCPS cohort includes 1,329,525 Koreans (846,907 men and 482,618 women) from 30 to 95 
years old who met the above selection criteria. The current analysis was limited to the 446,878 
participants who were the insured workers’ family dependents in 1993 and 1995. Insured 
workers were excluded from this study population because there was no WBC count record in 
their examinations. The 3,703 participants who reported a history of any cancer at enrollment 
and 1,483 participants who died of cancer before the start of follow-up were also excluded. 
Additionally, 17,273 participants with missing data on any covariate information were 
excluded from this study. After these exclusions, 424,419 participants (108,907 men and 
315,512 women), who received medical examination in 1993 and 1995, were included in the 
analyses.  
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Figure 1.  The framework of the current study 
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Figure 2.  The selection procedure of the study population  
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Data Collection 
 
The medical examinations were performed according to a standard procedure and 
conducted by the medical staffs at local hospitals. In the 1993 and 1995 questionnaires, 
participants were asked about smoking habits and other health behaviors. Participants were 
also asked if they were currently being treated for cancer or other diseases. If so, they were 
asked for the date of diagnosis. The completed questionnaires were reviewed by a trained staff 
and then entered into a database. The data were also checked and cleaned again during the 
analysis. Body mass index (BMI, kg/m2) was calculated as the ratio of weight (kilograms) 
divided by height squared (meters2). WBC count, fasting plasma glucose, and total cholesterol 
were measured under fasting conditions for routine clinical purposes. Each hospital had 
internal and external quality control procedures directed by the Korean Association of 
Laboratory Quality Control. Alcohol consumption per day was categorized as follows: not 
drinking (0 g), light drinking (1-29.9 g), and moderate to heavy drinking (30 g or more). 
Diabetes was defined as self-reported history of the disorder or when a fasting plasma glucose 
level was ≥126 mg/dL. Hypertension was defined as self-reported history of the disorder or 
when systolic blood pressure was ≥140 mmHg or diastolic blood pressure ≥90 mmHg.  
The maximum follow-up period was 10 years, from January 1, 1994 to December 31, 2003. 
The exact dates of completion of the survey form were not recorded in each year. 
Consequently, follow-up accrual began January 1 of the calendar year and ended in the year in 
which the survey form was completed. Subjects who completed a survey but died in the same 
calendar year were excluded.  
Because the study involved routinely collected medical data, it was not necessary to obtain 
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individual participant consent. The study was approved by both Institutional Review Boards of 
Yonsei University and the Johns Hopkins Bloomberg School of Public Health. 
 
Cancer Outcomes 
 
The primary outcomes were the mortality and incidence risk of colon and rectal cancer 
based on the National Cancer Registry data and hospitalization records. Although Korea has a 
National Cancer Registry, reporting may not have been complete during the time of follow-up. 
Thus, hospital administration files were used to identify the first admission date for cancer. 
Therefore, incident cancer cases were coded as occurring upon either registration to the 
National Cancer Registry or on a hospital admission due to cancer diagnosis. Mortality was 
ascertained from the death certificates. A computerized search of death certificate data from 
the National Statistical Office in Korea was performed using the unique identification number 
assigned at birth. Causes of death were assigned at the hospitals by trained abstractors. The 
analysis was limited to those deaths assigned to the 10th revision of the International 
Classification of Diseases (ICD-10); C18, malignant neoplasm of colon; C19, malignant 
neoplasm of rectosigmoid junction; and C20, malignant neoplasm of rectum.  
 
Statistical Analysis 
 
The chi-square test and one-way analysis of variance were used to analyze the statistical 
differences among characteristics of the study participants according to WBC counts at 
enrollment. Categorization of WBC counts into quartiles was based on the distribution of 
WBC counts among the study participants aged 40 to 95 years at baseline. Therefore, WBC 
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counts (cells/µL) were categorized as ≤5500, 5501-6500, 6501-7600, and >7600. In all 
primary analyses, the WBC count category of ≤5500 cells/µL was the reference group.  
Age-adjusted death and incidence rates were calculated for each category of WBC counts 
and were directly standardized to the age distribution of the Korean population in 1995. Cox 
proportional hazards regression models were used to compute hazard ratios (HRs) and its 95% 
confidence intervals (CIs), while adjusting for other potential risk factors. Cox models were 
also used to assess the trends in risk with quartiles of WBC count as a continuous variable. To 
exclude subclinical disease at baseline, we conducted analysis for the incidence of colon 
cancer after excluding cases that occurred within 2 years of follow-up. The association 
between WBC count and the incidence of colon cancer was also assessed by stratification 
according to smoking status in order to confirm that the association was independent of the 
effects of smoking on WBC count. 
All analyses were conducted using SAS statistical software, version 8.1 (SAS Institute Inc, 
Cary, NC). All statistical tests were two-sided, and statistical significance was determined at 
p<0.05. 
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RESULTS 
 
The baseline characteristics of the study population according to quartiles of WBC counts 
are shown in Tables 1 and 2. The mean BMI, systolic and diastolic blood pressure, fasting 
plasma glucose concentration, total cholesterol concentration, amount of daily alcohol 
consumption, smoking duration, and frequency of meat intake were increased with higher 
WBC count. The percentages of hypertension, diabetes, and current smoking were also 
increased with higher WBC count. Regular exercise was inversely associated with higher 
WBC count. 
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Table 1. Baseline characteristics of WBC counts in male participants by quartile * 
 
 Quartiles of WBC count, cells/µL p value  
 
 
≤5500 
(n=18,616) 
5501-6500 
(n=24,567) 
6501-7600 
(n=28,018) 
>7600 
(n=37,711) 
 
 
Age, year 63.3 (8.8) 62.6 (8.7) 62.4 (8.5) 61.8 (8.5) <0.0001 
Body mass index, kg/m2 22.2 (2.8) 22.6 (2.9) 22.7 (2.9) 22.8 (2.9) <0.0001 
Systolic blood pressure, mmHg 128.0 (20.5) 129.4 (21.0) 130.0 (21.0) 130.2 (21.1) <0.0001 
Diastolic blood pressure, mmHg 81.6 (13.0) 82.3 (13.1) 82.8 (13.3) 82.9 (13.2) <0.0001 
Fasting plasma glucose, mg/dL 95.9 (31.1) 96.5 (32.2) 96.6 (31.6) 97.6 (34.6) <0.0001 
Total cholesterol, mg/dL 183.5 (37.4) 188.8 (37.9) 191.3 (6.0) 194.0 (39.6) <0.0001 
Alcohol consumption, g/day 1.8 (6.9) 1.8 (6.9) 1.9 (6.0) 2.0 (6.1) 0.0379 
Smoking duration  29.4 (18.2) 30.8 (1.6) 31.8 (17.2) 33.7 (16.1) <0.0001 
Smoking status, %     <0.0001 
   Non smoker 26.2 22.5 20.1 15.6  
   Ex-smoker 31.0 29.0 26.7 22.5  
   Current smoker 42.7 48.5 53.2 61.9  
Regular exercise, % 33.3 32.2 31.1 29.1 <0.0001 
Meat intake, times /week, %     <0.0001 
   Nearly none 46.8 46.0 45.3 44.5  
   1-2  30.0 29.4 29.4 29.2  
   ≥ 3  23.2 24.6 25.3 26.3  
Hypertension, %† 33.4 35.9 36.9 37.4 <0.0001 
Diabetes, %‡ 8.0 8.4 8.6 9.6 <0.0001 
*Data are expressed as mean (SD) unless otherwise indicated. 
†Hypertension was defined as SBP≥ 140 mmHg, DBP ≥ 90 mmHg, or history of the disorder. 
‡Diabetes was defined as fasting plasma glucose level of at least 126 mg/dL (7.0 mmol/L) or history of the disorder. 
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Table 2. Baseline characteristics of WBC counts in female participants by quartile * 
 
 Quartile of WBC count, cells/µL p value  
 
 
≤5500 
(n=90,790) 
5501-6500 
(n=84,260) 
6501-7600 
(n=73,364) 
>7600 
(n=67,098) 
 
 
Age, year 53.9 (9.7) 54.5 (9.9) 55.0 (10.0) 55.8 (10.4) <0.0001 
Body mass index, kg/m2 23.5 (3.0) 23.9 (3.1) 24.2 (3.1) 24.4 (3.3) <0.0001 
Systolic blood pressure, mmHg 123.2 (19.9) 125.3 (20.7) 126.5 (21.1) 128.2 (21.7) <0.0001 
Diastolic blood pressure, mmHg 79.2 (12.9) 80.5 (13.3) 81.1 (13.4) 82.0 (13.6) <0.0001 
Fasting plasma glucose, mg/dL 90.7 (21.6) 92.4 (25.4) 93.8 (27.8) 96.3 (32.8) <0.0001 
Total cholesterol, mg/dL 194.5 (38.2) 199.2 (38.9) 201.7 (39.7) 205.6 (41.1) <0.0001 
Alcohol consumption, g/day 0.1 (0.6) 0.1 (0.7) 0.1 (1.1) 0.1 (0.6) 0.0379 
Smoking duration  4.8 (9.5) 5.8 (10.8) 6.7 (11.7) 8.3 (13.2) <0.0001 
Smoking status, %     <0.0001 
   Non smoker 94.0 92.2 90.6 87.7  
   Ex-smoker 2.3 2.8 3.1 3.6  
   Current smoker 3.8 5.1 6.3 8.7  
Regular exercise, % 19.2  18.6 18.3 17.3 <0.0001 
Meat intake, times /week, %     <0.0001 
   Nearly none 24.9 24.8 24.7 24.3  
   1-2 60.3 60.3 60.2 60.0  
   ≥ 3  14.8 14.9 15.1 15.7  
Hypertension, %† 23.9 27.9 30.1 33.2 <0.0001 
Diabetes, %‡ 3.6 5.0 6.2 8.6 <0.0001 
*Data are expressed as mean (SD) unless otherwise indicated. 
†Hypertension was defined as SBP≥ 140 mmHg, DBP ≥ 90 mmHg, or history of the disorder. 
‡Diabetes was defined as fasting plasma glucose level of at least 126 mg/dL (7.0 mmol/L) or history of the disorder. 
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Overall Patterns of All Cause Mortality  
 
During the 10 year follow-up, 25,458 and 21,482 deaths occurred among men and women, 
respectively. As shown Figure 3, WBC level was positively associated with age adjusted all-
cause mortality rates in women, whereas this figure seemed to be like U-shaped in men. The 
multivariate adjusted hazard ratios (HRs) for all cause mortality in the highest quartile of 
WBC count were 1.15 and 1.22 compared with the reference category in men (95% CI 1.11-
1.20, p for trend <0.0001) and women (95% CI 1.18-1.27, p for trend <0.0001), respectively 
(Tables 3, 4). 
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Figure 3. Age-adjusted mortality rate per 100,000 from all causes by quartile of WBC 
count in men and women, 1994-2003  
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Mortality Risk for Colon and Rectal Cancer 
 
For men, there were 9,010 deaths from all cancers including 310 from colon cancer and 
229 from rectal cancer during the 10 year follow-up. For women, there were 5,871 deaths 
from all cancers including 352 from colon cancer and 237 from rectal cancer. Tables 3 and 4 
show that the HRs for mortality from colon cancer increase with higher quartiles of WBC 
count among men and women. The multivariate adjusted HRs for all-cause mortality in the 
highest quartile of WBC count were 1.33 (95% CI 1.03-1.72, p for trend=0.0031) for 
colorectal cancer and 1.55 (95% CI 1.10-2.18, p for trend=0.0014) for colon cancer, compared 
with the reference category in men (Table 3). The higher mortality risk associated with higher 
quartiles of WBC count was also observed for colon cancer in women (highest versus lowest 
quartile: HR 1.51, 95% CI 1.12-2.03, p for trend=0.0049) (Table 4). In contrast to colon cancer, 
there was no significant difference in mortality risk for rectal cancer between the highest 
quartile and the lowest quartile in men or women. 
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Table 3. Age-adjusted mortality rate per 100,000 person-years and hazard ratios for all 
causes, all cancers, and colon and rectal cancer by quartile of WBC count in men, 1994-
2003* 
 
 
 
Quartile of WBC count, cells/µL  p value  
for trend 
 
 
≤5500 
(n=18,616) 
5501-6500 
(n=24,567) 
6501-7600 
(n=28,018) 
>7600 
(n=37,711) 
 
 
All causes, n 4,307 5,499 6,377 9,275  
   Death rate† 1513.3 1246.7 1306.1 1484.3  
   HR‡ 1.00 0.99(0.96-1.04) 1.02(0.98-1.06) 1.15(1.11-1.20) <0.0001 
All cancers, n 1,618 1,962 2,196 3,237  
   Death rate† 572.1 466.6 459.6 514.8  
   HR‡ 1.00 0.93(0.87-0.99) 0.90(0.85-0.96) 1.01(0.95-1.07) 0.3820 
Colorectal cancer, n 86 102 134 217  
   Death rate† 28.6 20.3 24.5 31.3  
   HR‡ 1.00 0.91(0.68-1.21) 1.06(0.81-1.40) 1.33(1.03-1.72) 0.0031 
Colon cancer, n 47 56 75 132  
   Death rate† 19.7 8.6 12.6 20.3  
   HR‡ 1.00 0.94(0.64-1.40) 1.10(0.76-1.59) 1.55(1.10-2.18) 0.0014 
Rectal cancer, n 39 46 59 85  
   Death rate† 8.9 11.7 11.9 11.0  
   HR‡ 1.00 0.90(0.58-1.39) 1.07(0.71-1.61) 1.22(0.83-1.80) 0.1555 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
*Participants with any of the following features at study entry were excluded: missing data on leukocyte count, existing 
cancer, and missing data on questionnaire. 
†The rate per 100,000 person-years is given, standardized to the age distribution of men in the 1995 Korean national 
population.  
‡The Cox proportional hazards model was adjusted for age, BMI, total cholesterol, smoking status, regular exercise, alcohol 
consumption per day (none, 0-29.9 g/day, ≥30 g/day), frequency of meat intake per week (nearly none, 1-2, ≥3), hypertension, 
and diabetes. 
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Table 4. Age-adjusted mortality rate per 100,000 person-years and hazard ratios for all 
causes, all cancers, colon and rectal cancer by quartile of WBC count in women, 1994-
2003* 
 
 
 
Quartile of WBC count, cells/µL 
 
p value  
for trend 
 
 
≤5500 
(n=90,790) 
5501-6500 
(n=84,260) 
6501-7600 
(n=73,364) 
>7600 
(n=67,098) 
 
 
All causes, n 5,134 5,220 5,159 5,969  
   Death rate† 622.9 632.6 677.3 791.5  
   HR‡ 1.00 1.01(0.98-1.05) 1.06(1.02-1.11) 1.22(1.18-1.27) <.0001 
All cancers, n 1,657 1,411 1,429 1,374  
   Death rate† 191.5 165.7 185.0 183.7  
   HR‡ 1.00 0.91(0.85-0.98) 1.01(0.94-1.08) 0.99(0.93-1.07) 0.6429 
Colorectal cancer, n 155 146 137 151  
   Death rate† 18.2 17.0 17.8 19.6  
   HR‡ 1.00 0.95(0.75-1.19) 1.00(0.79-1.26) 1.11(0.88-1.40) 0.3408 
Colon cancer, n 86 80 83 103  
   Death rate† 10.1 9.4 10.9 13.2  
   HR‡ 1.00 1.03(0.76-1.41) 1.18(0.87-1.61) 1.51(1.12-2.03) 0.0049 
Rectal cancer, n 69 66 54 48  
   Death rate† 8.1 7.6 6.9 6.4  
   HR‡ 1.00 0.98(0.69-1.39) 0.92(0.64-1.32) 0.79(0.54-1.16) 0.2179 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
*Participants with any of the following features at study entry were excluded: missing data on leukocyte count, existing 
cancer, and missing data on questionnaire. 
†The rate per 100,000 person-years is given, standardized to the age distribution of women in the 1995 Korean national 
population.  
‡The Cox proportional hazards model was adjusted for age, BMI, total cholesterol, smoking status, regular exercise, 
alcohol consumption per day (none, 0-29.9 g/day, ≥30 g/day), frequency of meat intake per week (nearly none, 1-2, ≥3), 
hypertension, and diabetes. 
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Incidence Risk for Colon and Rectal Cancer 
 
The incidences of colon cancer during the 10 year follow-up were 604 among men and 
838 among women. The trend of colorectal cancer incidence was generally similar to the 
mortality risk of colorectal cancer. Tables 5 and 6 show that the HRs for colon cancer 
incidence increase with the higher quartiles of WBC count. The multivariate adjusted HRs for 
incidence in the highest quartile of WBC count were 1.23 (95% CI 1.03-1.47, p for 
trend=0.0030) for colorectal cancer and 1.38 (95% CI 1.09-1.76, p for trend=0.0017) for colon 
cancer, compared with the reference category in men (Table 6). The higher incidence risk 
associated with an increased WBC count was also seen for colon cancer in women (highest 
versus lowest quartile: HR 1.46, 95% CI 1.20-1.78, p for trend=0.0003) (Table 6). There was 
no significant difference in incidence risk for rectal cancer between the highest quartile and 
the lowest quartile among men or women. A total 145 cases of colon cancer occurred within 2 
years of follow-up, 61 cases for men and 84 cases for women. Even after excluding these 
cases that occurred within 2 years of follow-up, this association was sustained. The 
multivariate adjusted HRs for incidence of colon cancer in the highest quartile of WBC count 
were 1.34 (95% CI 1.04-1.73, p for trend=0.0058) in men and 1.41 (95% CI 1.14-1.73, p for 
trend=0.0058) in women. 
 
 
 
 
 
 18 
Table 5. Age-adjusted incidence rate per 100,000 person-years and hazard ratios for all 
cancers, colon and rectal cancer by quartile of WBC count in men, 1994-2003* 
 
 
 
Quartile of WBC count, cells/µL 
 
p value  
for trend 
 
 
≤5500 
(n=18,616) 
5501-6500 
(n=24,567) 
6501-7600 
(n=28,018) 
>7600 
(n=37,711) 
 
 
All cancers, n 1,950 2,505 2,816 4,014  
   Incidence rate* 857.8 752.4 744.7 817.1  
   HR‡ 1.00 0.98(0.92-1.04) 0.96(0.90-1.01) 1.02(0.97-1.08) 0.2861 
Colorectal cancer n 183 228 276 435  
   Incidence rate* 89.8 59.8 78.1 83.6  
   HR‡ 1.00 0.95(0.78-1.15) 1.02(0.84-1.23) 1.23(1.03-1.47) 0.0030 
Colon cancer, n 94 123 149 238  
   Incidence rate* 43.2 31.7 42.0 49.2  
   HR‡ 1.00 1.00(0.76-1.31) 1.07(0.83-1.39) 1.38(1.09-1.76) 0.0017 
Rectal cancer, n 111 130 157 232  
   Incidence rate* 58.7 34.5 44.2 40.5  
   HR‡ 1.00 0.91(0.71-1.18) 0.99(0.77-1.26) 1.16(0.91-1.45) 0.0985 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
*Participants with any of the following features at study entry were excluded: missing data on leukocyte count, existing 
cancer, and missing data on questionnaire. 
†The rate per 100,000 person-years is given, standardized to the age distribution of men in the 1995 Korean national 
population.  
‡The Cox proportional hazards model was adjusted for age, BMI, total cholesterol, smoking status, regular exercise, 
alcohol consumption per day (none, 0-29.9 g/day, ≥30 g/day), frequency of meat intake per week (nearly none, 1-2, ≥3), 
hypertension, and diabetes. 
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Table 6. Age-adjusted incidence rate per 100,000 person-years and hazard ratios for all 
cancers, colon and rectal cancer by quartile of WBC count in women, 1994-2003*  
 
 
 
Quartile of WBC count, cells/µL 
 
p value  
for trend 
 
 
≤5500 
(n=90,790) 
5501-6500 
(n=84,260) 
6501-7600 
(n=73,364) 
>7600 
(n=67,098) 
 
 
All cancers, n 3,557 3,122 2,799 2,626  
   Incidence rate* 458.9 423.8 431.9 435.8  
   HR‡ 1.00 0.99(0.94-1.04) 1.00(0.95-1.06) 1.02(0.97-1.08) 0.3789 
Colorectal cancer, n 405 400 353 371  
   Incidence rate* 52.1 53.1 52.8 58.4  
   HR‡ 1.00 1.03(0.90-1.19) 1.03(0.89-1.19) 1.15(0.99-1.33) 0.0812 
Colon cancer, n 216 215 195 212  
   Incidence rate* 27.7 28.5 29.6 33.3  
   HR‡ 1.00 1.27(1.02-1.50) 1.26(1.03-1.54) 1.46(1.20-1.78) 0.0003 
Rectal cancer, n 228 222 183 189  
   Incidence rate* 29.3 29.5 27.1 30.1  
   HR‡ 1.00 1.10(0.91-1.32) 1.04(0.85-1.27) 1.14(0.93-1.39) 0.2987 
Abbreviations: CI, confidence interval; HR, hazard ratio 
*Participants with any of the following features at study entry were excluded: missing data on leukocyte count, existing 
cancer, and missing data on questionnaire. 
†The rate per 100,000 person-years is given, standardized to the age distribution of women in the 1995 Korean national 
population.  
‡The Cox proportional hazards model was adjusted for age, BMI, total cholesterol, smoking status, regular exercise, alcohol 
consumption per day (none, 0-29.9 g/day, ≥30 g/day), frequency of meat intake per week (nearly none, 1-2, ≥3), 
hypertension, and diabetes. 
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Incidence Risk for Colon Cancer according to Smoking status  
 
We also assessed the association between WBC count and incidence of colon cancer after 
stratification by smoking status (non-smokers, ex-smokers, and current smokers) in order to 
confirm that the associations were independent of the effects of smoking on WBC count. 
Among men who reported never smoking, a positive linear trend was observed between 
the incidence of colon cancer and WBC count. The multivariate adjusted HRs for incidence of 
colon cancer were 1.56 (95% CI 0.83-2.95), 2.61 (95% CI 1.45-4.68), and 2.90 (95% CI 1.62-
5.17) with increasing WBC count quartiles, compared with a reference quartile (p for trend 
<0.0001) (Figure 4). A similar positive linear trend was also observed in female non-smokers. 
The multivariate adjusted HRs for colon cancer incidence were 1.27 (95% CI 1.04-1.55), 1.26 
(95% CI 1.02-1.55), 1.47 (95% CI 1.19-1.81) with increasing WBC count quartiles, compared 
with a reference quartile (p for trend=0.0006) (Figure 5). However, there was no significant 
difference in incidence of colon cancer among ex-smokers and current smokers (Figures 4, 5). 
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Figure 4. Hazard ratios* for colon cancer incidence by quartile of WBC count in men by 
smoking status, 1994-2003 (*The Cox proportional hazards model was adjusted for age, BMI, total cholesterol, 
regular exercise, alcohol consumption per day (none, 0-29.9 g/day, ≥30 g/day), frequency of meat intake per week 
(nearly none, 1-2, ≥3), hypertension, and diabetes.) 
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Figure 5. Hazard ratios* for colon cancer incidence by quartile of WBC count in women 
by smoking status, 1994-2003 (*The Cox proportional hazards model was adjusted for age, BMI, total 
cholesterol, regular exercise, alcohol consumption per day (none, 0-29.9 g/day, ≥30 g/day), frequency of meat intake 
per week (nearly none, 1-2, ≥3), hypertension, and diabetes 
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DISCUSSION 
 
In this large prospective cohort study of Korean men and women, a positive association 
between WBC count and the risk of colon cancer was found. Our data suggest that an elevated 
WBC count increases the incidence risk and mortality of colon cancer in men and women. 
These findings are consistent with emerging evidence suggesting that inflammation increases 
the risk of colon cancer. Individuals with long-term inflammatory bowel disease, in particular 
ulcerative colitis, are at higher risk for developing colorectal cancer than ordinary individuals 
(Levin, 1992). A clinical trial demonstrates that regular use of anti-inflammatory agents can 
reduce the risk of colorectal adenoma, a well-known precancerous lesion (Baron, 2003). In a 
recent prospective cohort study examining the association between WBC count and the 
mortality risk of cancers, an elevated WBC count increased the mortality risk for all cancers. 
However, the study failed to show this association through subgroup analyses including colon, 
breast, and prostate cancer (Erlinger, 2004). This may be due to the lower number of deaths 
from the site-specific cancers mentioned. 
There are two previous prospective studies with conflicting results on the relationship 
between inflammatory markers and the incidence of colorectal cancer. In a recent nested case-
control study of 172 colorectal cases (131 colon cases, 41 rectal cases) within the CLUE II 
cohort in which 22,887 residents of Washington County, Maryland were studied prospectively, 
the incidence risk of colon cancer increased with higher CRP levels. However, this association 
was not found in rectal cancer (Erlinger, 2004). On the contrary, a different prospective study 
with 27,913 healthy women within the Women’s Health Study showed that a high CRP level 
was not a predictive risk factor for the development of colorectal cancer (Zhang, 2005). 
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Despite a positive association between WBC count and the incidence risk and mortality of 
colon cancer, we did not find a similarly significant association with rectal cancer in the 
present study. A potential limitation of the CLUE II cohort study is a relatively smaller number 
of rectal cancer patients (n=41), which could have weakened the association between an 
elevated CRP level and the incidence of rectal cancer. Our study overcomes this weakness by 
conducting prospective follow-ups on a larger number of rectal cancer patients during a 10 
year follow-up period. Accordingly, our findings implicate that the role of inflammation 
involved in the development of colon cancer may be different from that of rectal cancer. The 
biological mechanisms through which an elevated WBC count increases the risk of colon 
cancer have not yet been established. However, several plausible mechanisms between colon 
cancer and inflammation deserve consideration based on previous studies. Cyclooxygenase-2 
(COX-2) may be linked to the pathogenesis of colon cancer development. COX-2 protein is 
over-expressed and the prostaglandin E2 level is elevated in the portal vein and colonic 
mucosa in human colorectal cancers (Oka, 1994; Pugh, 1994). COX-2 protein may control 
angiogenesis by modulating production of the vascular endothelial growth factor (VEGF), 
which promotes sustained endothelial cell proliferation and vascular permeability in 
tumorogenesis (Yancopoulos, 2000; Tsujii, 1998). Many other studies also demonstrate that 
the carcinogenic effect of inflammation may be linked to DNA damage in proliferative cells 
(Maeda, et al. 1998), alteration of p53 tumor suppressor gene (Chen, 2005), inhibition of 
apoptosis (Sheng, 1998) during the various stages of carcinogenesis. Dietary and lifestyle risk 
factors for colon cancer, such as a diet high in calories, animal fat, and/or refined 
carbohydrates, physical inactivity, central obesity, and high body mass index are also related to 
inflammation and insulin resistance (Verdaet, 2004; Wolever, 1996). Insulin resistance may 
lead to tumor growth by elevating bioavailable insulin growth factor-1 (IGF-1) and decreasing 
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insulin growth factor binding protein-1 (IGFBP-1) (Ma, 2004). These inflammatory effects on 
colon cancer may not only be through systemic pathway mediated by cytokines and 
chemokines but also directly linked to the colon epithelium. A recent study shows that 
individuals with more risk factors for colorectal cancer have a higher level of calprotectin, 
which is a marker of bowel inflammation at the tissue level (Poullis, 2004). 
Our study has several potential limitations to take into consideration. First, WBC counts 
during the 10 year follow-up were not available for our study. Thus, only one measurement of 
WBC count, at baseline examination, was included in the analysis. Therefore, it was not 
possible to determine whether an acute, brief episode of inflammation or chronic inflammation 
was responsible for the correlation found in the current study. Second, data on potentially 
confounding factors, such as past medical history of inflammatory bowel disease or colorectal 
polyps, medication history (aspirin, other NSAIDs or estrogen use) were unavailable in the 
baseline questionnaire. Thus, such variables are not fully adjusted in our Cox-proportional 
hazards regression model. Lastly, the study population in our cohort, particularly the older 
aged population, might not be representative of the general population in Korea.  
Despite these potential limitations, the current study has several important strengths. First, 
the current study is a large prospective study with a relatively long period of follow-up, so we 
can be confident about the temporal relationship between inflammation and the risk of colon 
cancer. Second, this positive association was sustained even after excluding the cases of colon 
cancer that developed within the first 2 years of follow-up, thereby reducing the likelihood of 
a subclinical cancer at the baseline of the study. Consequently, the elevated WBC count was 
unlikely to be caused and biased by a subclinical colon cancer. Finally, similar positive trends 
observed in non-smokers suggest that the incidence risk of colon cancer associated with an 
elevated WBC count is independent of the effects of smoking on WBC count.  
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In conclusion, our findings demonstrate that an elevated WBC count is a predictor of the 
incidence risk and mortality of colon cancer. These results support our hypothesis that 
inflammation increases the risk of colon cancer. Further observational and experimental 
studies are needed to confirm these findings and to determine the role of inflammation in the 
carcinogenesis of colon and rectal cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
REFERENCES 
 
National Cancer Information Center. 2002 Annual report of the Korea central cancer registry. 
Goyang: National Cancer Information Center, 2003. http://www.ncc.re.kr (accessed 
June 27, 2005) 
Korea National Statistical Office. Death Statistics based on vital registration 2002. Daejeon: 
Korea National Statistical Office, 2003. http://kosis.nso.go.kr/cgi-
bin/sws_777pop.cgi?A_REPORT_ID=MA&A_CONTENTS=1501&A_LANG=1 
(accessed June 27, 2005) 
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R. et al. A randomized trial of 
aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.  
Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Bronner MP, Brentnall TA. The initiation of 
colon cancer in a chronic inflammatory setting. Carcinogenesis 2005; (Epub ahead of 
print). 
Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 1985; 153: 9-1. 
Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features 
of children, adolescents and young adults with colorectal carcinoma. Gut 2005; 54: 
1146-50. 
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident 
colorectal cancer. JAMA 2004; 291: 585-90.  
Erlinger TP, Muntner P, Helzlsouer KJ. WBC count and the risk of cancer mortality in a 
national sample of U.S. adults: results from the Second National Health and Nutrition 
Examination Survey mortality study. Cancer Epidemiol Biomarkers Prev 2004; 13: 
 28 
1052-6. 
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment 
of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N 
Engl J Med 1993; 328: 1313-6.  
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use 
and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern 
Med 1994; 121: 241-6. 
Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk 
in Korean men and women. JAMA 2005; 293: 194-202. 
Levin B. Inflammatory bowel disease and colon cancer. Cancer 1992; 70: 1313-6. 
Lüchtenborg M, Weijenberg MP, Kampman E, van Muijen GN, Roemen GM, Zeegers MP, et 
al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1  expression, and 
GSTM1 and GSTT1 polymorphisms. Am J Epidemiol 2005; 161: 806-15. 
Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of 
plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Ins 2004; 96: 546-
53. 
Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer, 
Biochemistry 1998; 63: 854-65 
Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, et al. BMI and 
waist circumference as predictors of lifetime colon cancer risk in Framingham study 
aduluts. Int J Obes Relat Metab Disord 2004; 28: 559-67. 
Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. Diet and 
colorectal adenoma in Japanese males and females. Dis Colon Rectum 2001; 44: 105-
11. 
 29 
Oka M, Inaba A, Uchiyama T, Hazama S, Shimoda K, Suzuki M, et al. Prostaglandin E2 
levels and lymphocyte subsets in portal venous drainage of colorectal cancers. Am J 
Surg 1994; 167: 264-7.  
Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured 
by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. 
Cancer Epidemiol Biomarkers Prev 2004; 13: 279-84. 
Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased 
colonic mucosal prostaglandin E2. Gut 1994; 35: 675-678.  
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-
2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 
362-6. 
Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, et al. Height, weight, 
and alcohol consumption in relation to the risk of colorectal cancer in Japan: a 
prospective study. Br J Cancer 2003; 88: 1038-43. 
Slattery ML, Edwards S, Curtin K, Ma K, Edwards R, Holubkov R, et al. Physical activity and 
colorectal cancer. Am J Epidemiol 2003; 158: 214-24. 
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates 
angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16. 
Verdaet D, Dendale P, De Bacquer D, Delanghe J, Block P, De Backer G. Association between 
leisure time physical activity and markers of chronic inflammation related to coronary 
heart disease. Atherosclerosis 2004; 176: 303-10. 
Wolever TM, Bolognesi C, Prediction of glucose and insulin responses of normal subjects 
after consuming mixed meals varying in energy, protein, fat, carbohydrate and 
glycemic index. J Nutr 1996; 126: 2807-12. 
 30 
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific 
growth factors and blood vessel formation. Nature 2000; 407: 242-8. 
Zalokar JB, Richard JL, Claude JR. Leukocyte count, smoking, and myocardial infarction. N 
Engl J Med 1981; 304: 465-8. 
Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not 
associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 
142: 425-32. 
 
 
 
 
 
 
 
 
 
 
 
 31 
국문 요약 
 
연구배경 
염증이 대장암, 직장암 발생과 관련있을 것이라는 가설이 꾸준히 제시되고 
있으나, 최근 비특이적 염증지표인 C-reactive protein (CRP)가 대장암, 직장암의 
발생위험을 높인다는 보고와 대장암, 직장암 발생과 관련이 없다는 상반된 역학 
연구가 발표되었다.  
 
연구목적 
저자들은 전향적인 대규모 코호트 연구를 통해 비특이적 염증지표인 
백혈구수와 대장암, 직장암 발생의 관계에 대해 알아보고자 한다.  
 
연구방법 
한국 암 예방 연구 코호트 (Korean Cancer Prevention Study : KCPS) 중에서 
연구시작 당시 백혈구수 측정이 가능했던 40세 – 95세 사이의 424,319명 (남 : 
108,907명, 여 : 315,512명)을 대상으로 백혈구수 구간을 4구간으로 구분한 후 
1994년부터 2003년까지 대장암, 직장암의 발생률 및 사망률과 각각의 
상대위험도를 구하였다. 또한, 흡연여부에 따른 대장암 발생의 상대위험도를 
구하였다.  
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연구결과 
10년의 추적관찰 기간 동안 제 4구간의 대장암으로 인한 사망위험이 
기준집단에 비해 남성에서는 1.55배 높았으며 (95% 신뢰구간 1.10-2.18, p for 
trend=0.0014), 여성에서는 1.51배 높았다 (95% 신뢰구간 1.12-2.03, p for 
trend=0.0049).  
대장암 발생도 대장암으로 인한 사망과 비슷한 양상이었다. 제 4구간의 대장암 
발생 위험이 기준집단에 비해 남성에서는 1.38배 높았으며 (95% 신뢰구간 1.09-
1.76, p for trend=0.0017), 여성에서는 1.46배 높았다 (1.20-1.78, p for 
trend=0.0003). 흡연여부에 따른 대장암 발생의 위험도 남성과 여성 모두 
비흡연자에서 대장암 발생의 상대위험도가 높았다. 남성과 여성 모두 백혈구수 
구간별 직장암 발생과 사망의 상대위험도는 유의한 차이가 없었다. 
 
 
결론 
비특이적 염증지표인 백혈구수가 높을수록 대장암 발생의 위험과 사망의 위험이 
높아진다.  
 
